Evidence map›Paper›PMID 35746444›Full record

ArticleVaccines2022

mRNA COVID-19 Vaccine Reactogenicity among Healthcare Workers: Results from an Active Survey in a Pediatric Hospital from Bucharest, January-February 2021.

Maria-Dorina Crăciun, Gabriela Viorela Nițescu, Mihaela Golumbeanu, Alina-Andreea Tănase, Daniela Pițigoi, Oana Săndulescu, Petru Crăciun, Bianca Georgiana Enciu, Radu Ninel Bălănescu, Alexandru Ulici

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Maria-Dorina CrăciunDepartment of Epidemiology, University of Medicine and Pharmacy "Carol Davila", 020021 Bucharest, Romania.ORCID 0000-0003-1052-7730
Gabriela Viorela NițescuEmergency Clinical Hospital for Children "Grigore Alexandrescu", 011743 Bucharest, Romania.
Mihaela GolumbeanuEmergency Clinical Hospital for Children "Grigore Alexandrescu", 011743 Bucharest, Romania.
Alina-Andreea TănaseEmergency University Hospital, 050098 Bucharest, Romania.
Daniela PițigoiDepartment of Epidemiology, University of Medicine and Pharmacy "Carol Davila", 020021 Bucharest, Romania.ORCID 0000-0003-4118-8268
Oana SăndulescuDepartment of Epidemiology, University of Medicine and Pharmacy "Carol Davila", 020021 Bucharest, Romania.ORCID 0000-0002-2586-4070
Petru CrăciunDepartment of Drug Industry, University of Medicine and Pharmacy "Carol Davila", 020021 Bucharest, Romania.
Bianca Georgiana EnciuDepartment of Epidemiology, University of Medicine and Pharmacy "Carol Davila", 020021 Bucharest, Romania.
Radu Ninel BălănescuEmergency Clinical Hospital for Children "Grigore Alexandrescu", 011743 Bucharest, Romania.
Alexandru UliciEmergency Clinical Hospital for Children "Grigore Alexandrescu", 011743 Bucharest, Romania.ORCID 0000-0003-1018-1506
Carol Davila University of Medicine and Pharmacy · ROClinical Emergency Hospital Bucharest · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Romania, health and social workers were prioritized for COVID-19 vaccination. We aimed to describe the vaccine adverse events identified through an active survey (using an electronic questionnaire) conducted among the staff of a pediatric hospital from Bucharest, vaccinated with the mRNA Pfizer-BioNTech vaccine. Data on the frequency and duration of adverse events were collected and analyzed using Microsoft Excel, Epi Info, and MedCalc. The questionnaire was sent to 426 persons. The participation rate was 81.2% after 1st dose and 63.8% after the 2nd dose. Overall, 81.9% were women, median age 42 (IQR 32-50 years). A total of 48 respondents (14.8%) reported no adverse event after the 1st dose and 35 (14.1) after the 2nd dose. No anaphylaxis was reported. The most frequent adverse event was pain at injection site, being reported by 261 responders (80.3%) after 1st dose and 187 (75.1%) after 2nd dose. Fatigue and headache were reported significantly less frequently in our study compared with data provided by the vaccine manufacturer. The current study has shown higher local reactogenicity after the first dose of the vaccine and higher systemic reactogenicity after the second dose. This real-world knowledge of the reactogenicity and safety profile may increase the vaccine's acceptance rate among healthcare workers.

Indexed as

active surveillanceCOVID-19healthcare workersmRNA vaccinereactogenicity

Identifiers

PMID35746444
PMCPMC9230821
OpenAlexW4281489617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.